Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Drug companies call for antibiotic funding
Pills in bottle
Antibiotic resistance has increased so much in recent years that it is now considered to be a serious risk to public health.
Government urged to take urgent action

Pharmaceutical companies and industry bodies are warning of a "terrible human cost" unless new ways to fund antibiotics can be found.

In an open letter published in the Financial Times, the organisations urge the government to take urgent action. They also highlight warnings that around 10 million people a year could be killed by drug-resistant bacteria by 2050.

They write that without new antibiotics "everything from routine surgical procedures, to cancer chemotherapy, organ transplantation and even childbirth will become increasingly dangerous."

They add that if we fail to act now, "antimicrobial resistance is also expected to cost the world economy $100tn a year by 2050."

Antibiotic resistance has increased so much in recent years that it is now considered to be a serious risk to public health.

In 2014,the lack of existing antibiotics, together with the lack of new antibiotic treatments led the World Health Organisation to describe the situation as a "post-antibiotic era", where people can die from simple infections that have been treatable for decades.

The letter was signed by professor Colin Garner, chief executive of Antibiotic Research UK; prof Jayne Lawrence, chief scientist at the Royal Pharmaceutical Society; John Rex, a senior AstraZeneca executive; prof Luigi Martini, of King's College London; and Jeremy Lefroy MP.

The letter was also signed by Bioindustry Association chief executive Steve Bates, who told BBC News that companies' investment "needed to be rewarded," but without encouraging the overuse of antibiotics.

He suggested that the government set up a insurance-style scheme in which it paid a fixed fee for antibiotics, so that manufacturers didn't just focus on research into drugs that increased sales. 

Become a member or log in to add this story to your CPD history

Animal Medicines Amnesty returns this November

News Story 1
 Veterinary practices are being urged to help owners safely dispose of any unused and expired pet medicines - not just antibiotics - during November's Animal Medicines Amnesty.

Organised by the Responsible Use of Medicines Alliance Companion Animal and Equine (RUMA CA&E), the initative is supported by a range of cross-sector organisations.

Practices are encouraged to use the campaign to engage the whole practice team and raise awareness of the safe disposal of medicines with clients. Learn how your practice can get involved at rumacae.org.uk 

Click here for more...
News Shorts
APHA launches free virtual work experience programme

The Animal and Plant Health Agency (APHA), in collaboration with Springpod, has launched a free virtual work experience programme, giving young people across the UK the chance to explore careers dedicated to protecting animal and plant health.

The on-demand programme offers a unique insight into career opportunities within APHA, showcasing how students can contribute to tackling some of the UK's most critical biosecurity and environmental challenges.

Designed for students aged 13 and over, the course includes more than 10 hours of engaging content featuring real-life industry insights, scenario-based challenges, and practical guidance on applying for jobs. To register for the course, visit the APHA website.